Nkarta (NASDAQ:NKTX) Price Target Lowered to $14.00 at Mizuho

Nkarta (NASDAQ:NKTX) had its price objective trimmed by Mizuho from $16.00 to $14.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other equities analysts also recently issued reports about the stock. William Blair reissued a “market perform” rating on shares of Nkarta in a research note on Thursday, May 15th. Stifel Nicolaus decreased their price target on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, March 27th. Needham & Company LLC decreased their price target on shares of Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, May 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Nkarta in a research note on Thursday, March 27th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $14.33.

Nkarta Price Performance

NKTX stock opened at $1.99 on Tuesday. The firm’s fifty day simple moving average is $1.83 and its 200-day simple moving average is $2.07. The company has a market capitalization of $141.21 million, a P/E ratio of -1.06 and a beta of 0.72. Nkarta has a 12 month low of $1.31 and a 12 month high of $8.23.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.01. As a group, sell-side analysts forecast that Nkarta will post -1.7 earnings per share for the current year.

Institutional Trading of Nkarta

Several institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP increased its stake in Nkarta by 4.1% in the 4th quarter. Wellington Management Group LLP now owns 225,224 shares of the company’s stock valued at $561,000 after buying an additional 8,883 shares during the period. JPMorgan Chase & Co. lifted its holdings in Nkarta by 138.7% in the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company’s stock valued at $6,319,000 after purchasing an additional 1,474,560 shares in the last quarter. Deutsche Bank AG lifted its holdings in Nkarta by 26.1% in the 4th quarter. Deutsche Bank AG now owns 43,157 shares of the company’s stock valued at $107,000 after purchasing an additional 8,946 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Nkarta by 41.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company’s stock valued at $60,000 after purchasing an additional 7,030 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its holdings in Nkarta by 18.3% in the 4th quarter. Nuveen Asset Management LLC now owns 140,113 shares of the company’s stock valued at $349,000 after purchasing an additional 21,627 shares in the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.